Committee OKs Retrospective Studies, But With Caveats

FDA's Oncologic Drugs Advisory Committee agreed that retrospective studies can be used to support predictive biomarkers. The agency convened the meeting in hopes of coming away with guidance on how to assess forthcoming applications to restrict therapies to patients, using predictive biomarkers